Lobbying Activity Report

204-17561

Organization: AstraZeneca Canada Inc.
Associated registration: 8188-204-24
Lobbying Activity date: 2022-04-07
Arranged a meeting: Yes
Posted date: 2022-05-16

In-house lobbyists who participated in the lobbying activity: Ilias Iliopoulos
Kiersten Combs
Noel Saraza
Senior Public Office Holders who were lobbied in this activity: Tijana Fazlagic, Executive Director
Pharmacare Benefits Branch, Health

I Fan Kuo, Director, Evaluation and Optimal Use
Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Discussions with BC government officials/organizations and elected representative to obtains public reimbursement of AstraZeneca Canada (AZC) innovative treatments for BC Citizens that require access to these treatments. These discussions will take place with BC government funded programs such as Pharmacare, and the BC Cancer Agency. This will include discussions on how best to conclude Product Listing Agreement discussions with each of these public entities.
  • Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health
Provide supply chain availability updates on AstraZeneca Canada medicines including vaccines, deemed essential for COVID-19 acute and community care.
  • Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 COVID-19
 
Senior officer who filed this Lobbying Activity Report: Kiersten Combs
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
Date Modified: